HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Key facts

Sponsor

Sun Yat-sen University

Intervention

HAI Adebrelimab(procedure)

Enrollment

76 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2028

Study locations (1)

• Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Collaborators

Henan Provincial People's Hospital · First Affiliated Hospital of Fujian Medical University · Shanghai Zhongshan Hospital · Cancer Hospital of Guangxi Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07521852
  A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
  TaiRx, Inc.
• RECRUITINGPHASE2NCT07504471
  Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
  Ruijin Hospital
• RECRUITINGNCT07295275
  Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
  West China Hospital
• RECRUITINGPHASE2NCT07324824
  Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
  Sun Yat-sen University
• RECRUITINGEARLY PHASE1NCT07193862
  Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
  Northwell Health
• RECRUITINGPHASE1, PHASE2NCT07282184
  Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
  Tongji Hospital
• RECRUITINGNCT07170345
  Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
  Chinese Academy of Sciences
• RECRUITINGPHASE2NCT07099274
  Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital

See all trials for Fibrolamellar hepatocellular carcinoma →